Afrezza vs ORMD-0801

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin · full Type 2 Diabetes pipeline

Afrezza

Marketed by MannKind Corporation and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT00332488 · Phase 3 · completed

The trial randomized 528 participants across three treatment groups and used an active comparator, but it was open-label rather than blinded and its primary endpoint was the surrogate measure HbA1c. The primary comparison was not met: HbA1c decreased by 0.70% with inhaled insulin plus metformin versus 0.78% with metformin plus secretagogue (p=0.420).

Reported efficacy

Change in HbA1c from baseline to week 26 (non-inferiority vs rapid-acting insulin analog, margin 0.4%): HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. (missed)

Result source: NCT04974528

ORMD-0801

Developed by Lifeward Ltd. and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT04606576 · Phase 3 · terminated

This is a large, randomized, fully blinded, placebo-controlled trial using blood sugar control (A1C), the standard disease-defining measure for diabetes, as its primary endpoint, a well-designed setup for showing a real treatment effect. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: April 2027 · NCT06731075 (registry estimate)

Reported efficacy

Mean change from baseline in A1C (Baseline and 26 Weeks): Phase 3 ORA-D-013-1 (710 patients): ORMD-0801 vs placebo, primary endpoint (mean change from baseline in HbA1c at 26 weeks) not met; secondary endpoint (fasting plasma glucose change) also not met. (missed)

Result source: NCT04606576

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAfrezzaORMD-0801
HbA1c, change-0.7% vs -0.8%vs Metformin & Secretagogueswk 12 · n 169NCT00332488
3 other results
  • 0.1% vs -0.8% wk 12 · n 133 · Phase 3 · secondary NCT00332488
  • -1.8% vs -1.2% wk 24 · n 29 · Phase 3 · secondary NCT00332488
  • -1.7% vs -1.2% wk 24 · n 77 · Phase 3 · secondary NCT00332488
-0.6% vs -0.1%−0.5 vs placeboOnce Daily (QHS) · wk 12 · n 59NCT03467932
8 other results
  • -0.6% vs -0.1% Twice Daily (BID) · wk 12 · n 54 · Phase 2 · primary NCT03467932
  • -0.5% vs -0.1% Three Times Daily (TID) · wk 12 · n 52 · Phase 2 · primary NCT03467932
  • 0.1% vs -0.1% 16 mg Once Daily (QHS) · wk 12 · n 13 · Phase 2 · primary NCT03467932
  • -0.9% vs -0.1% 8 mg Once Daily (QHS) · wk 12 · n 13 · Phase 2 · primary NCT03467932
  • -0.9% vs -0.1% 8 mg Twice Daily (BID) · wk 12 · n 12 · Phase 2 · primary NCT03467932
  • -0.5% vs -0.1% 16 mg Twice Daily (BID) · wk 12 · n 10 · Phase 2 · primary NCT03467932
  • 0% vs 0.2% Dose 1 · wk 4 · n 53 · Phase 2 · secondary NCT02496000
  • -0.0% vs 0.2% 1.5 * Dose 1 · wk 4 · n 59 · Phase 2 · secondary NCT02496000
Body weight, change (kg)—Not posted · NCT00539890—Trial running · NCT06731075
HbA1c below 7%—Not posted · NCT00539890—Trial running · NCT06731075
Fasting plasma glucose, change—Not posted · NCT00539890—Trial running · NCT06731075
3-point MACE (% with event)—Not posted · NCT00539890—Trial running · NCT06731075

HbA1c, change

Afrezza
-0.7% vs -0.8%vs Metformin & Secretagogueswk 12 · n 169NCT00332488
3 other results
  • 0.1% vs -0.8% wk 12 · n 133 · Phase 3 · secondary NCT00332488
  • -1.8% vs -1.2% wk 24 · n 29 · Phase 3 · secondary NCT00332488
  • -1.7% vs -1.2% wk 24 · n 77 · Phase 3 · secondary NCT00332488
ORMD-0801
-0.6% vs -0.1%−0.5 vs placeboOnce Daily (QHS) · wk 12 · n 59NCT03467932
8 other results
  • -0.6% vs -0.1% Twice Daily (BID) · wk 12 · n 54 · Phase 2 · primary NCT03467932
  • -0.5% vs -0.1% Three Times Daily (TID) · wk 12 · n 52 · Phase 2 · primary NCT03467932
  • 0.1% vs -0.1% 16 mg Once Daily (QHS) · wk 12 · n 13 · Phase 2 · primary NCT03467932
  • -0.9% vs -0.1% 8 mg Once Daily (QHS) · wk 12 · n 13 · Phase 2 · primary NCT03467932
  • -0.9% vs -0.1% 8 mg Twice Daily (BID) · wk 12 · n 12 · Phase 2 · primary NCT03467932
  • -0.5% vs -0.1% 16 mg Twice Daily (BID) · wk 12 · n 10 · Phase 2 · primary NCT03467932
  • 0% vs 0.2% Dose 1 · wk 4 · n 53 · Phase 2 · secondary NCT02496000
  • -0.0% vs 0.2% 1.5 * Dose 1 · wk 4 · n 59 · Phase 2 · secondary NCT02496000

Body weight, change (kg)

Afrezza
—Not posted · NCT00539890
ORMD-0801
—Trial running · NCT06731075

HbA1c below 7%

Afrezza
—Not posted · NCT00539890
ORMD-0801
—Trial running · NCT06731075

Fasting plasma glucose, change

Afrezza
—Not posted · NCT00539890
ORMD-0801
—Trial running · NCT06731075

3-point MACE (% with event)

Afrezza
—Not posted · NCT00539890
ORMD-0801
—Trial running · NCT06731075
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Afrezza: 4 of 4 rows · ORMD-0801: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAfrezzaORMD-0801
Dropout rate
32%TI Inhalation Powder + Metformina
NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 6 more results
27.3%TI Inhalation Powder Alone
NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Dose 1
NCT04849845 · Phase 4 · registry result, not featured evidence
—Dose 2
NCT04849845 · Phase 4 · registry result, not featured evidence
0%
NCT03324776 · Phase 3 · registry result, not featured evidence
—60 U
NCT00570687 · Phase 2 · registry result, not featured evidence
—90 U
NCT00570687 · Phase 2 · registry result, not featured evidence
—16 mg Once Daily (QD)b
NCT03467932 · Phase 2
show 19 more results
11.1%16 mg Once Daily (QHS)
NCT03467932 · Phase 2
11.8%8 mg Twice Daily (BID)
NCT03467932 · Phase 2
—8 mg Once Daily (QD)
NCT03467932 · Phase 2
13.3%8 mg Once Daily (QHS)
NCT03467932 · Phase 2
26.7%16 mg Twice Daily (BID)
NCT03467932 · Phase 2
—Once Daily (QD)
NCT03467932 · Phase 2
10.1%Once Daily (QHS)
NCT03467932 · Phase 2
15.9%Three Times Daily (TID)
NCT03467932 · Phase 2
14.7%Twice Daily (BID)
NCT03467932 · Phase 2
0%QD
NCT04616014 · Phase 2 · registry result, not featured evidence
9.5%8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
16.7%
NCT04564846 · Phase 2 · registry result, not featured evidence
—Dose 1
NCT02954601 · Phase 2 · registry result, not featured evidence
—Dose 2
NCT02954601 · Phase 2 · registry result, not featured evidence
0%Dose 3
NCT02954601 · Phase 2 · registry result, not featured evidence
8.2%Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence
3.2%1.5 * Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence
0%ORMD-0801 Dose # 1
NCT01889667 · Phase 2 · registry result, not featured evidence
0%ORMD-0801 Dose # 2
NCT01889667 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.4%TI Inhalation Powder + Metformina
NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 6 more results
4.4%TI Inhalation Powder Alone
NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Dose 1
NCT04849845 · Phase 4 · registry result, not featured evidence
—Dose 2
NCT04849845 · Phase 4 · registry result, not featured evidence
—
NCT03324776 · Phase 3 · registry result, not featured evidence
—60 U
NCT00570687 · Phase 2 · registry result, not featured evidence
—90 U
NCT00570687 · Phase 2 · registry result, not featured evidence
—16 mg Once Daily (QD)b
NCT03467932 · Phase 2
show 19 more results
—16 mg Once Daily (QHS)
NCT03467932 · Phase 2
—8 mg Twice Daily (BID)
NCT03467932 · Phase 2
—8 mg Once Daily (QD)
NCT03467932 · Phase 2
—8 mg Once Daily (QHS)
NCT03467932 · Phase 2
—16 mg Twice Daily (BID)
NCT03467932 · Phase 2
—Once Daily (QD)
NCT03467932 · Phase 2
—Once Daily (QHS)
NCT03467932 · Phase 2
—Three Times Daily (TID)
NCT03467932 · Phase 2
—Twice Daily (BID)
NCT03467932 · Phase 2
—QD
NCT04616014 · Phase 2 · registry result, not featured evidence
4.8%8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
—
NCT04564846 · Phase 2 · registry result, not featured evidence
—Dose 1
NCT02954601 · Phase 2 · registry result, not featured evidence
—Dose 2
NCT02954601 · Phase 2 · registry result, not featured evidence
—Dose 3
NCT02954601 · Phase 2 · registry result, not featured evidence
—Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence
—1.5 * Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence
—ORMD-0801 Dose # 1
NCT01889667 · Phase 2 · registry result, not featured evidence
—ORMD-0801 Dose # 2
NCT01889667 · Phase 2 · registry result, not featured evidence
Serious AEs
3.1%TI Inhalation Powder + Metformina
NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 6 more results
2.8%TI Inhalation Powder Alone
NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%Dose 1
NCT04849845 · Phase 4 · registry result, not featured evidence
0%Dose 2
NCT04849845 · Phase 4 · registry result, not featured evidence
0%
NCT03324776 · Phase 3 · registry result, not featured evidence
0%60 U
NCT00570687 · Phase 2 · registry result, not featured evidence
0%90 U
NCT00570687 · Phase 2 · registry result, not featured evidence
0%16 mg Once Daily (QD)b
NCT03467932 · Phase 2
show 19 more results
—16 mg Once Daily (QHS)
NCT03467932 · Phase 2
0%8 mg Twice Daily (BID)
NCT03467932 · Phase 2
0%8 mg Once Daily (QD)
NCT03467932 · Phase 2
—8 mg Once Daily (QHS)
NCT03467932 · Phase 2
6.7%16 mg Twice Daily (BID)
NCT03467932 · Phase 2
7.2%Once Daily (QD)
NCT03467932 · Phase 2
—Once Daily (QHS)
NCT03467932 · Phase 2
4.3%Three Times Daily (TID)
NCT03467932 · Phase 2
0%Twice Daily (BID)
NCT03467932 · Phase 2
0%QD
NCT04616014 · Phase 2 · registry result, not featured evidence
4.8%8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
0%
NCT04564846 · Phase 2 · registry result, not featured evidence
0%Dose 1
NCT02954601 · Phase 2 · registry result, not featured evidence
0%Dose 2
NCT02954601 · Phase 2 · registry result, not featured evidence
0%Dose 3
NCT02954601 · Phase 2 · registry result, not featured evidence
1.6%Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence
0%1.5 * Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence
0%ORMD-0801 Dose # 1
NCT01889667 · Phase 2 · registry result, not featured evidence
0%ORMD-0801 Dose # 2
NCT01889667 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
hypoglycaemia 23.9%
cough 17.7%
nasopharyngitis 5.1%
NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 5 more results
cough 27.1%
hypoglycaemia 13.3%
upper respiratory tract infection 3.9%
NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Dose 1
cough 5%
NCT04849845 · Phase 4 · registry result, not featured evidence
Dose 2
cough 10%
NCT04849845 · Phase 4 · registry result, not featured evidence
60 U
cough 66.7%
phlebitis 16.7%
acute sinusitis 0%
NCT00570687 · Phase 2 · registry result, not featured evidence
90 U
cough 83.3%
nasopharyngitis 16.7%
acute sinusitis 0%
NCT00570687 · Phase 2 · registry result, not featured evidence
16 mg Once Daily (QD)b
anemia 5.6% (placebo 0%)
abdominal discomfort 0% (placebo 1.2%)
abdominal pain upper 0% (placebo 0%)
NCT03467932 · Phase 2
show 14 more results
8 mg Twice Daily (BID)
anemia 5.9% (placebo 0%)
cystitis 5.9% (placebo 1.2%)
abdominal discomfort 0% (placebo 1.2%)
NCT03467932 · Phase 2
8 mg Once Daily (QD)
constipation 6.7% (placebo 0%)
cystitis 6.7% (placebo 1.2%)
diarrhoea 6.7% (placebo 3.7%)
NCT03467932 · Phase 2
16 mg Twice Daily (BID)
diverticulitis 6.7% (placebo 0%)
nausea 6.7% (placebo 1.2%)
abdominal discomfort 0% (placebo 1.2%)
NCT03467932 · Phase 2
Once Daily (QD)
anemia 4.3% (placebo 0%)
atrial fibrillation 4.3% (placebo 0%)
diarrhoea 2.9% (placebo 3.7%)
NCT03467932 · Phase 2
Three Times Daily (TID)
diarrhoea 11.6% (placebo 3.7%)
nausea 1.4% (placebo 1.2%)
seasonal allergy 1.4% (placebo 1.2%)
NCT03467932 · Phase 2
Twice Daily (BID)
diarrhoea 4.4% (placebo 3.7%)
anemia 1.5% (placebo 0%)
atrial fibrillation 1.5% (placebo 0%)
NCT03467932 · Phase 2
QD
diarrhia 57.1%
steatorrhea 28.6%
bronchitis 14.3%
NCT04616014 · Phase 2 · registry result, not featured evidence
8 mg BD
addominal distention 23.8% (placebo 0%)
nausea 9.5% (placebo 0%)
atrial fibrillation 4.8% (placebo 9.1%)
NCT04618744 · Phase 2 · registry result, not featured evidence
gastrointestinal disorders 12.5% (placebo 0%)
headache 12.5% (placebo 8%)
abdominal pain 4.2% (placebo 0%)
NCT04564846 · Phase 2 · registry result, not featured evidence
metabolism and nutrional disorders 25% (placebo 22.6%)
gastrointestinal disorders 5% (placebo 9.7%)
hypoglycemia 5% (placebo 6.5%)
NCT02954601 · Phase 2 · registry result, not featured evidence
metabolism and nutrional disorders 28.6% (placebo 22.6%)
hypoglycemia 19% (placebo 6.5%)
gastrointestinal disorders 9.5% (placebo 9.7%)
NCT02954601 · Phase 2 · registry result, not featured evidence
metabolism and nutrional disorders 10% (placebo 22.6%)
eye disorders 5% (placebo 0%)
hypoglycemia 5% (placebo 6.5%)
NCT02954601 · Phase 2 · registry result, not featured evidence
number 30% (placebo 50%)
NCT01889667 · Phase 2 · registry result, not featured evidence
number 40% (placebo 50%)
NCT01889667 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 5 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Afrezza

PP 2 h Excursion mg/dL 88.6 mg/dL @ 0.012wkDose 1
absolute value · mg/dL
No placebo or comparator arm
120 minutes PPGE
NCT04849845 · Phase 4 · registry result, not featured evidence
show 1 more result
36.9 mg/dL @ 0.012wkDose 2
120 minutes PPGE
NCT04849845 · Phase 4 · registry result, not featured evidence
HbA1c 1.6% (n=20) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT03324776 · Phase 3 · registry result, not featured evidence
show 1 more result
0.435% @ 26wk
NCT04974528 · Phase 3 · sponsor-reported, not registry data
HbA1c Less Than 7% 20% (n=20) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT03324776 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
Time Below 70 mg/dL 2.6% (n=20) @ 12wk
absolute value · percentage points
No placebo or comparator arm
NCT03324776 · Phase 3 · registry result, not featured evidence

ORMD-0801

HbA1c Change mmol/Mol -2.06 vs -2.12 placebo mmol/mol @ 3wk16 mg Once Daily (QHS)
absolute change · mmol/mol
NCT03467932 · Phase 2
show 13 more results
-0.25 vs -1.27 placebo mmol/mol @ 10wk16 mg Once Daily (QD)
NCT03467932 · Phase 2
-3.26 vs -2.12 placebo mmol/mol @ 3wk8 mg Once Daily (QHS)
NCT03467932 · Phase 2
-5.51 vs -2.12 placebo mmol/mol @ 3wk8 mg Twice Daily (BID)
NCT03467932 · Phase 2
-10.34 vs -1.27 placebo mmol/mol @ 10wk8 mg Once Daily (QD)
NCT03467932 · Phase 2
-10.71 vs -1.27 placebo mmol/mol @ 10wk8 mg Twice Daily (BID)
NCT03467932 · Phase 2
-1.87 vs -2.12 placebo mmol/mol @ 3wk16 mg Twice Daily (BID)
NCT03467932 · Phase 2
-4.66 vs -1.27 placebo mmol/mol @ 10wk16 mg Twice Daily (BID)
NCT03467932 · Phase 2
-2.56 vs -2.12 placebo mmol/mol @ 3wkOnce Daily (QHS)
NCT03467932 · Phase 2
-1.95 vs -2.12 placebo mmol/mol @ 3wkTwice Daily (BID)
NCT03467932 · Phase 2
-2.91 vs -2.12 placebo mmol/mol @ 3wkThree Times Daily (TID)
NCT03467932 · Phase 2
-5.95 vs -1.27 placebo mmol/mol @ 10wkOnce Daily (QD)
NCT03467932 · Phase 2
-4.95 vs -1.27 placebo mmol/mol @ 10wkTwice Daily (BID)
NCT03467932 · Phase 2
-6.16 vs -1.27 placebo mmol/mol @ 10wkThree Times Daily (TID)
NCT03467932 · Phase 2
Liver PDFF 0.3271% (n=7) @ 12wkQD
percent change · % of baseline
No placebo or comparator arm
Change from Screening in MR PDFF
NCT04616014 · Phase 2 · registry result, not featured evidence
Liver Stiffness FibroScan Change kPa -0.6571 kiloPascals (kPa) @ 12wkQD
absolute change · kiloPascals (kPa)
No placebo or comparator arm
Mean Change between week -6 and week 12 Fibroscan Fibrosis (Elasticity)
NCT04616014 · Phase 2 · registry result, not featured evidence
Liver Steatosis Cap Change DB 10.7129 dB/M @ 12wkQD
absolute change · dB/M
No placebo or comparator arm
Change from Screening in Fibroscan CAP
NCT04616014 · Phase 2 · registry result, not featured evidence
Liver PDFF -7.105% (n=19) vs -1.103% (n=9) placebo @ 12wk8 mg BD
percent change · % of baseline
NCT04618744 · Phase 2 · registry result, not featured evidence
show 7 more results
-7.489% (n=19) vs -6.526% (n=9) placebo @ 12wk8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
-6.424% (n=19) vs 0% (n=9) placebo @ 12wk8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
-10.763% (n=19) vs 0.105% (n=9) placebo @ 12wk8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
-6.488% (n=19) vs -4.965% (n=9) placebo @ 12wk8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
-9.31% (n=19) vs -9.891% (n=9) placebo @ 12wk8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
-5.419% (n=19) vs -6.376% (n=9) placebo @ 12wk8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
14.817% (n=19) vs 17.451% (n=9) placebo @ 12wk8 mg BD
NCT04618744 · Phase 2 · registry result, not featured evidence
Liver Stiffness FibroScan Change kPa -0.8 vs 0.3 placebo kPa (kilo Pascals) @ 12wk8 mg BD
absolute change · kPa (kilo Pascals)
NCT04618744 · Phase 2 · registry result, not featured evidence
HbA1c 8.67% (n=20) vs 9.19% (n=22) placebo @ 4.14wk
absolute value · percentage points
Day 29 HbA1c
NCT04564846 · Phase 2 · registry result, not featured evidence
HbA1c 0.15% (n=20) vs 0.08% (n=22) placebo @ 4.14wk
absolute change · percentage points
Difference of HbA1c between baseline and Day 29
NCT04564846 · Phase 2 · registry result, not featured evidence
Daily Plasma Glucose Change mg/dL -1.09 vs -1.09 placebo mmol/L @ 4.14wk
absolute change · mmol/L
Change in Plasma Glucose from Baseline
NCT04564846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -19.6 mg/dL as posted
Glucose Change mg/dL -0.56 vs -0.27 placebo mmol/L @ 1.14wk
absolute change · mmol/L
NCT02954601 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -10 mg/dL as posted
show 5 more results
-0.07 vs -0.27 placebo mmol/L @ 1.14wk*
NCT02954601 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -1.21 mg/dL as posted
-0.63 vs -0.27 placebo mmol/L @ 1.14wk*
NCT02954601 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -11.42 mg/dL as posted
-0.77 vs -0.23 placebo mmol/L @ 1.14wk*
NCT02954601 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.96 mg/dL as posted
0.06 vs -0.23 placebo mmol/L @ 1.14wk*
NCT02954601 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 1.13 mg/dL as posted
-0.93 vs -0.23 placebo mmol/L @ 1.14wk*
NCT02954601 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -16.78 mg/dL as posted
Night Time Glucose Change mg/dL -0.2 vs 0.76 placebo mmol/L @ 4wkDose 1
absolute change · mmol/L
NCT02496000 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -3.67 mg/dL as posted
show 1 more result
0.37 vs 0.76 placebo mmol/L @ 4wk*1.5 * Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 6.64 mg/dL as posted
24 h Glucose 3.33% (n=54) vs 5.34% (n=56) placebo @ 4wkDose 1
percent change · % of baseline
NCT02496000 · Phase 2 · registry result, not featured evidence
show 1 more result
1.93% (n=59) vs 5.34% (n=56) placebo @ 4wk1.5 * Dose 1
NCT02496000 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afrezza's landscape · ORMD-0801's landscape